Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$2.65 +5.8%	$1.51	$1.05 ▼ $4.13	$262.33M	1.54	611,778 shs	1.14 million shs
CRVS Corvus Pharmaceuticals	$3.78 +3.0%	$3.41	$1.75 ▼ $10.00	$257.68M	0.67	730,437 shs	590,430 shs
LXRX Lexicon Pharmaceuticals	$0.70 +1.4%	$0.57	$0.28 ▼ $2.45	$252.83M	1.07	6.61 million shs	3.68 million shs
SBOT Stellar Biotechnologies	$12.65 -1.2%	$59,624.23	$0.75 ▼ $3.25	$67.42M	N/A	2.95 million shs	5.80 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	+5.80%	+35.29%	+81.15%	+65.83%	-25.91%
CRVS Corvus Pharmaceuticals	+3.00%	+4.13%	+8.00%	-4.06%	+87.13%
LXRX Lexicon Pharmaceuticals	+1.36%	+13.98%	+1.66%	+4.39%	-58.62%
SBOT Stellar Biotechnologies	+12.96%	+28.74%	+97.08%	+36.71%	+392.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADCT ADC Therapeutics	2.1641 of 5 stars	3.5	2.0	0.0	0.0	3.1	0.8	0.6
CRVS Corvus Pharmaceuticals	2.1572 of 5 stars	3.5	1.0	0.0	0.0	2.4	2.5	0.6
LXRX Lexicon Pharmaceuticals	2.7736 of 5 stars	4.2	2.0	0.0	0.0	2.4	1.7	0.6
SBOT Stellar Biotechnologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	3.00	Buy	$7.75	193.01% Upside
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	296.83% Upside
LXRX Lexicon Pharmaceuticals	2.40	Hold	$3.67	424.26% Upside
SBOT Stellar Biotechnologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SBOT, ADCT, LXRX, and CRVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	CRVS Corvus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$12.00 ➝ $11.00
5/15/2025	ADCT ADC Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$8.00 ➝ $8.00
5/9/2025	CRVS Corvus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$15.00 ➝ $17.00
3/31/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $7.00
3/31/2025	ADCT ADC Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
3/28/2025	LXRX Lexicon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
3/26/2025	CRVS Corvus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$14.00 ➝ $15.00
3/26/2025	CRVS Corvus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
3/7/2025	ADCT ADC Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/7/2025	LXRX Lexicon Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $6.00
3/5/2025	LXRX Lexicon Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$75.82M	3.46	N/A	N/A	($1.93) per share	-1.37
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$0.79 per share	N/A
LXRX Lexicon Pharmaceuticals	$31.21M	8.10	N/A	N/A	$0.38 per share	1.84
SBOT Stellar Biotechnologies	$210K	321.07	N/A	N/A	$2.12 per share	5.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$240.05M	-$1.45	N/A	N/A	N/A	-300.00%	N/A	-61.33%	8/5/2025 (Estimated)
CRVS Corvus Pharmaceuticals	-$27.03M	-$0.98	N/A	N/A	N/A	N/A	-70.71%	-45.90%	8/5/2025 (Estimated)
LXRX Lexicon Pharmaceuticals	-$177.12M	-$0.51	N/A	N/A	N/A	-4,109.41%	-107.38%	-64.09%	8/7/2025 (Estimated)
SBOT Stellar Biotechnologies	-$5.03M	-$1.76	N/A	N/A	N/A	-1,782.64%	-51.12%	-48.37%	N/A

Latest SBOT, ADCT, LXRX, and CRVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ADCT ADC Therapeutics	-$0.38	-$0.36	+$0.02	-$0.36	$17.71 million	$23.03 million
5/13/2025	Q1 2025	LXRX Lexicon Pharmaceuticals	-$0.10	-$0.07	+$0.03	-$0.07	$1.26 million	$1.26 million
5/8/2025	Q1 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.13	N/A	-$0.13	N/A	N/A
3/27/2025	Q4 2024	ADCT ADC Therapeutics	-$0.35	-$0.29	+$0.06	-$0.29	$19.01 million	$19.00 million
3/25/2025	Q4 2024	CRVS Corvus Pharmaceuticals	-$0.12	-$0.18	-$0.06	-$0.18	N/A	N/A
3/6/2025	Q4 2024	LXRX Lexicon Pharmaceuticals	-$0.11	-$0.09	+$0.02	-$0.09	$6.48 million	$26.55 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SBOT Stellar Biotechnologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.92	4.68
CRVS Corvus Pharmaceuticals	N/A	0.92	0.92
LXRX Lexicon Pharmaceuticals	0.56	7.45	7.43
SBOT Stellar Biotechnologies	N/A	9.24	8.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
CRVS Corvus Pharmaceuticals	46.64%
LXRX Lexicon Pharmaceuticals	74.70%
SBOT Stellar Biotechnologies	1.69%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	4.10%
CRVS Corvus Pharmaceuticals	31.30%
LXRX Lexicon Pharmaceuticals	6.80%
SBOT Stellar Biotechnologies	7.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	99.18 million	92.73 million	Optionable
CRVS Corvus Pharmaceuticals	30	68.17 million	44.15 million	Optionable
LXRX Lexicon Pharmaceuticals	140	361.49 million	229.49 million	Optionable
SBOT Stellar Biotechnologies	25	5.33 million	N/A	Not Optionable

SBOT, ADCT, LXRX, and CRVS Headlines

Recent News About These Companies

Serve Robotics ties up with Alphabet's unit for drone deliveries, launching pilot in Texas

October 1, 2024 | reuters.com

Are robots the future of food delivery? Serve Robotics thinks so

May 5, 2024 | finance.yahoo.com

Uber, Nvidia-backed Serve Robotics hits public markets with $40M splash

April 18, 2024 | techcrunch.com

Stellar Blade Demo Walkthrough

April 17, 2024 | ign.com

Been Stellar

March 11, 2024 | nme.com

The real reason Terry Biviano signed up to be a Housewife

October 31, 2023 | dailytelegraph.com.au

Zach Wilson’s stellar day at Jets camp includes long touchdown throw

July 30, 2023 | nypost.com

Caterpillar's Stellar Move To Attract High-Quality Employees

June 7, 2023 | forbes.com

Audio-Technica AT2020USB-X review - Simple for stellar streaming

May 10, 2023 | techradar.com

Ravens Expect to Bring Back Stellar Offensive Line

February 26, 2023 | si.com

2023 NFL combine: Detroit Lions could re-invest in their stellar offensive line

February 26, 2023 | mlive.com

Stellar Bancorp, Inc. Declares Quarterly Dividend

February 26, 2023 | benzinga.com

MSU-Mankato rallies past Dragons women with stellar 3rd-quarter performance

February 5, 2023 | inforum.com

O's closer Felix Bautista goes on DL ending stellar rookie year

October 5, 2022 | cbsnews.com

Daniel Ryan one of the stellar cast members of new gripping BBC thriller Crossfire partly set in Leicester

September 24, 2022 | leicestermercury.co.uk

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBOT, ADCT, LXRX, and CRVS Company Descriptions

ADC Therapeutics NYSE:ADCT

$2.64 +0.15 (+5.80%)

Closing price 05/28/2025 03:59 PM Eastern

Extended Trading

$2.57 -0.08 (-2.99%)

As of 05/28/2025 06:20 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Corvus Pharmaceuticals NASDAQ:CRVS

$3.78 +0.11 (+3.00%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$3.73 -0.05 (-1.43%)

As of 05/28/2025 07:59 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Lexicon Pharmaceuticals NASDAQ:LXRX

$0.70 +0.01 (+1.36%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$0.70 0.00 (-0.06%)

As of 05/28/2025 07:55 PM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Stellar Biotechnologies NASDAQ:SBOT

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time